Multiple myeloma - lenalidomide (post bortezomib) (part rev TA171): Evaluation report
Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.
It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.
If you have any feedback on the new format please contact the Project Manager for this appraisal.
01 - Pre-Meeting Briefing
02 - Final Scope and Final Matrix of Consultees and Commentators
03 - Manufacturers submission
04 - NICE request to the manufacturer for clarification
05 - Manufacturer's response to NICE's request for clarification
06 - NICE request to the manufacturer for further clarification
07 - Manufacturer's response to the request for further clarification
08 - Consultee submission from Myeloma UK
09 - Clinical expert personal perspective - Davies
10 - Patient expert personal perspective - Dewinter
11 - Patient expert personal perspective - Low
12 - Evidence Review Group report
13 - Erratum to the Evidence Review Group report
14 - Manufacturer factual accuracy check of Evidence Review Group report
15 - ERG response to the manufacturer factual accuracy check
Multiple myeloma - lenalidomide (post bortezomib) (part rev TA171): Evaluation report
14 March 2014 (6.58 Mb 41 sec) |
This page was last updated: 13 March 2014